ADVANCED ONCOLOGY CERTIFIED NURSE PRACTITIONER
(AOCNP®) CERTIFICATION EXAM - LATEST PRACTICE
QUESTIONS AND 100% VERIFIED CORRECT ANSWERS |
COMPLETE EXAM PREP TESTBANK | GUARANTEED PASS |
INSTANT DOWNLOAD PDF
This comprehensive, exam-ready assessment is designed to mirror the structure and content outline of the
Advanced Oncology Certified Nurse Practitioner (AOCNP®) certification administered by the
Oncology Nursing Certification Corporation (ONCC).
Content Domains Covered (150 Questions Total):
Cancer biology, genetics, genomics, and tumor immunology
Cancer screening, prevention, and risk reduction
Diagnostic evaluation, staging, and prognostic indicators
Treatment modalities: chemotherapy, immunotherapy, targeted therapy, hormonal therapy,
radiation, surgery, cellular therapy
Symptom management and oncologic emergencies
Hematologic malignancies and solid tumors
Survivorship and long-term follow-up
Palliative and end-of-life care
Professional practice, ethics, legal considerations, research, and evidence-based practice
Leadership, quality improvement, and safety
1. A 58-year-old patient with newly diagnosed non–small cell lung cancer asks
about the role of PD-L1 testing. The AOCNP explains that PD-L1 testing
primarily guides:
A. Surgical candidacy
B. Radiation dosing
C. Immunotherapy selection
D. Chemotherapy toxicity prediction
Rationale: PD-L1 expression helps determine eligibility and expected response to
immune checkpoint inhibitors.
, 2. A patient receiving anthracycline therapy should undergo baseline
evaluation of:
A. Renal function
B. Left ventricular ejection fraction (LVEF)
C. Pulmonary function tests
D. Thyroid function
Rationale: Anthracyclines carry risk of cardiomyopathy; baseline and periodic
LVEF assessment is required.
3. Tumor lysis syndrome is most commonly associated with:
A. Early-stage colon cancer
B. Hormonal therapy
C. High-grade lymphomas and leukemias
D. Radiation dermatitis
Rationale: Rapid tumor cell breakdown in hematologic malignancies leads to TLS.
4. A patient on cisplatin reports tinnitus. The most appropriate action is:
A. Reassure patient
B. Administer diuretics
C. Continue therapy unchanged
D. Evaluate for ototoxicity and notify oncology team
Rationale: Cisplatin can cause ototoxicity; early detection prevents irreversible
damage.
5. BRCA1 mutation increases risk primarily for:
A. Thyroid cancer
, B. Pancreatic neuroendocrine tumor
C. Breast and ovarian cancer
D. Melanoma
Rationale: BRCA1 mutations significantly elevate breast and ovarian cancer risk.
6. First-line management of febrile neutropenia includes:
A. Oral antibiotics at home
B. Broad-spectrum IV antibiotics within 1 hour
C. Growth factor alone
D. Delay until cultures return
Rationale: Febrile neutropenia is an oncologic emergency requiring prompt IV
antibiotics.
7. HER2 overexpression in breast cancer predicts benefit from:
A. Tamoxifen
B. Bevacizumab
C. Trastuzumab
D. Methotrexate
Rationale: Trastuzumab targets HER2 receptor-positive tumors.
8. The most common dose-limiting toxicity of carboplatin is:
A. Neurotoxicity
B. Cardiotoxicity
C. Myelosuppression
D. Hepatotoxicity
Rationale: Carboplatin commonly causes thrombocytopenia and neutropenia.
, 9. A patient receiving immune checkpoint inhibitors develops diarrhea. The
priority assessment is:
A. Dietary intake
B. Hemoglobin
C. Severity and frequency of stools
D. Electrolytes only
Rationale: Immune-mediated colitis can become severe; grading severity guides
management.
10.For extravasation of vesicant chemotherapy, the first action is:
A. Remove IV and apply pressure
B. Flush line
C. Stop infusion immediately
D. Apply heat universally
Rationale: Immediate cessation prevents further tissue damage.
11.PSA screening discussions should include:
A. Universal recommendation
B. No risks
C. Shared decision-making
D. Mandatory annual screening
Rationale: PSA screening requires individualized discussion of benefits/harms.
12.SIADH in small cell lung cancer results in:
A. Hypernatremia
B. Hyponatremia
(AOCNP®) CERTIFICATION EXAM - LATEST PRACTICE
QUESTIONS AND 100% VERIFIED CORRECT ANSWERS |
COMPLETE EXAM PREP TESTBANK | GUARANTEED PASS |
INSTANT DOWNLOAD PDF
This comprehensive, exam-ready assessment is designed to mirror the structure and content outline of the
Advanced Oncology Certified Nurse Practitioner (AOCNP®) certification administered by the
Oncology Nursing Certification Corporation (ONCC).
Content Domains Covered (150 Questions Total):
Cancer biology, genetics, genomics, and tumor immunology
Cancer screening, prevention, and risk reduction
Diagnostic evaluation, staging, and prognostic indicators
Treatment modalities: chemotherapy, immunotherapy, targeted therapy, hormonal therapy,
radiation, surgery, cellular therapy
Symptom management and oncologic emergencies
Hematologic malignancies and solid tumors
Survivorship and long-term follow-up
Palliative and end-of-life care
Professional practice, ethics, legal considerations, research, and evidence-based practice
Leadership, quality improvement, and safety
1. A 58-year-old patient with newly diagnosed non–small cell lung cancer asks
about the role of PD-L1 testing. The AOCNP explains that PD-L1 testing
primarily guides:
A. Surgical candidacy
B. Radiation dosing
C. Immunotherapy selection
D. Chemotherapy toxicity prediction
Rationale: PD-L1 expression helps determine eligibility and expected response to
immune checkpoint inhibitors.
, 2. A patient receiving anthracycline therapy should undergo baseline
evaluation of:
A. Renal function
B. Left ventricular ejection fraction (LVEF)
C. Pulmonary function tests
D. Thyroid function
Rationale: Anthracyclines carry risk of cardiomyopathy; baseline and periodic
LVEF assessment is required.
3. Tumor lysis syndrome is most commonly associated with:
A. Early-stage colon cancer
B. Hormonal therapy
C. High-grade lymphomas and leukemias
D. Radiation dermatitis
Rationale: Rapid tumor cell breakdown in hematologic malignancies leads to TLS.
4. A patient on cisplatin reports tinnitus. The most appropriate action is:
A. Reassure patient
B. Administer diuretics
C. Continue therapy unchanged
D. Evaluate for ototoxicity and notify oncology team
Rationale: Cisplatin can cause ototoxicity; early detection prevents irreversible
damage.
5. BRCA1 mutation increases risk primarily for:
A. Thyroid cancer
, B. Pancreatic neuroendocrine tumor
C. Breast and ovarian cancer
D. Melanoma
Rationale: BRCA1 mutations significantly elevate breast and ovarian cancer risk.
6. First-line management of febrile neutropenia includes:
A. Oral antibiotics at home
B. Broad-spectrum IV antibiotics within 1 hour
C. Growth factor alone
D. Delay until cultures return
Rationale: Febrile neutropenia is an oncologic emergency requiring prompt IV
antibiotics.
7. HER2 overexpression in breast cancer predicts benefit from:
A. Tamoxifen
B. Bevacizumab
C. Trastuzumab
D. Methotrexate
Rationale: Trastuzumab targets HER2 receptor-positive tumors.
8. The most common dose-limiting toxicity of carboplatin is:
A. Neurotoxicity
B. Cardiotoxicity
C. Myelosuppression
D. Hepatotoxicity
Rationale: Carboplatin commonly causes thrombocytopenia and neutropenia.
, 9. A patient receiving immune checkpoint inhibitors develops diarrhea. The
priority assessment is:
A. Dietary intake
B. Hemoglobin
C. Severity and frequency of stools
D. Electrolytes only
Rationale: Immune-mediated colitis can become severe; grading severity guides
management.
10.For extravasation of vesicant chemotherapy, the first action is:
A. Remove IV and apply pressure
B. Flush line
C. Stop infusion immediately
D. Apply heat universally
Rationale: Immediate cessation prevents further tissue damage.
11.PSA screening discussions should include:
A. Universal recommendation
B. No risks
C. Shared decision-making
D. Mandatory annual screening
Rationale: PSA screening requires individualized discussion of benefits/harms.
12.SIADH in small cell lung cancer results in:
A. Hypernatremia
B. Hyponatremia
